Chardan Capital analyst Keay Nakae reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report) yesterday and set a price ...

The share price in Arrowhead Pharmaceuticals Inc. jumped by more than 48% in the two months since it hit its lowest value of the past year. On Oct. 10, ...

Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigatio ...

Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...

A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...

Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shareholders should be happy to see the share price up 11% in the ...

Shares of Arrowhead Pharmaceuticals Inc. ($ARWR) and Sarepta Therapeutics Inc. ($SRPT) climbed on Wednesday despite Wall ...

Pick the best stocks and maximize your portfolio: Smith covers the Healthcare sector, focusing on stocks such as Halozyme, Twist Bioscience, and Arrowhead Pharmaceuticals. According to TipRanks, Smith ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its target price cut by Piper Sandler from $62.00 to $45.00 in a ...

Not exactly known for its dealmaking, Sarepta Therapeutics has thrown down a massive wad of cash to work with Arrowhead ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its price target trimmed by Citigroup from $27.00 to $26.00 in a ...